Related Experiment Video

Updated: Aug 14, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Should HIV/HCV coinfected patients with severe hepatitis be treated for hepatitis C

J K Rockstroh1

  • 1Medizinische Universitätsklinik I, Bonn. juergen.rockstroh@ukb.uni-bonn.de

Presse Medicale (Paris, France : 1983)
|November 30, 2005
PubMed

Insights

Hepatitis C (HCV) treatment is recommended for HIV-positive patients due to faster liver disease progression. Combination therapy with peginterferon and ribavirin shows promising results for sustained virologic response in coinfected individuals.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • One-third of HIV patients are coinfected with hepatitis C virus (HCV).
  • HIV-HCV coinfection accelerates liver disease progression and increases mortality.
  • Antiretroviral therapies can have hepatotoxic effects.

Purpose of the Study:

  • To evaluate the efficacy and safety of treating hepatitis C in HIV-infected patients.
  • To determine the optimal treatment duration and response predictors for HCV in coinfected individuals.
  • To assess the impact of highly active antiretroviral treatments (HAART) on HCV course.

Main Methods:

  • Assessed a combination therapy of peginterferon and ribavirin in HIV-HCV coinfected patients.
  • Recommended a 48-week treatment duration irrespective of HCV genotype.
  • Monitored early virologic response at 12 weeks as a predictive factor for sustained response.

Main Results:

  • Combination therapy demonstrated satisfactory prolonged virologic response rates.
  • Early virologic response at 12 weeks predicted sustained response.
  • HAART appeared to positively influence the course of hepatitis C, outweighing hepatotoxicity risks.

Conclusions:

  • Hepatitis C treatment is crucial for HIV-coinfected patients to improve outcomes.
  • Peginterferon and ribavirin combination therapy is effective for sustained virologic response.
  • Early response assessment guides treatment decisions, and HAART may benefit HCV management.

More Related Videos

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...